Enhanced Bilayer Tablets for Improved Stability and Efficacy

The present inventive concept relates to improved bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, featuring enhanced formulations and packaging to reduce degradation and improve treatment outcomes for the common cold and flu.

The original patent disclosed bilayer tablets with acetylsalicylic acid and pseudoephedrine, but these tablets suffered from degradation due to hydrolysis and oxidation, leading to reduced efficacy over time. The new inventive concept addresses these limitations by introducing moisture-absorbing excipients, vacuum drying, and antioxidant formulations to improve the stability and shelf life of the tablets.

The enhanced bilayer tablets comprise an acetylsalicylic acid layer formulated with a moisture-absorbing excipient, such as silica gel or calcium chloride, to reduce hydrolysis-induced degradation. The granules are prepared using a dissolution aid and then dried under vacuum to minimize moisture content. The pseudoephedrine layer is formulated with an antioxidant, such as vitamin E or beta-carotene, to reduce oxidation-induced degradation. The tablets are packaged in a low-humidity environment using a desiccant packet to maintain their stability during storage and transportation. The inventive concept also includes a system for delivering the tablets, comprising a tablet dispenser adapted to dispense a single bilayer tablet at a time, and a method for using the tablets, involving monitoring the patient's symptoms to adjust the dosage regimen as needed.

The new claims introduce the use of moisture-absorbing excipients, vacuum drying, and antioxidant formulations to improve the stability and shelf life of the bilayer tablets, which is not disclosed in the original patent. These features provide a non-obvious solution to the problem of degradation and improve the overall efficacy of the tablets.

Alternative embodiments of the inventive concept may include using different moisture-absorbing excipients, such as zeolites or alumina, or different antioxidant formulations, such as ascorbic acid or tocopherol. The tablets may also be packaged in blister packs or other containers with desiccant materials to maintain a low-humidity environment.

The enhanced bilayer tablets have significant commercial potential in the pharmaceutical industry, particularly in the over-the-counter (OTC) market for cold and flu treatments. The improved stability and efficacy of the tablets can provide a competitive advantage in the market and improve treatment outcomes for patients.